Drugs for Bilirubin Metabolic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 78)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Oxytocin |
Approved, Vet_approved |
Phase 4 |
|
50-56-6 |
439302 53477758 |
Synonyms:
(2S)-2-[({1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-N-[(C-hydroxycarbonimidoyl)methyl]-4-methylpentanimidate
(Arg8)-vasopressin
(Arg8)-vasotocin
[<sup>3</sup>H]oxytocin
alpha-Hypophamine
Argipressin
Argpressin acetate
Biotinyl-(arg8)-vasopressin
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
Disulfide bridge cys1-cys6
Gly-leu-pro-c
Ocytocin
|
ORASTHIN
Oxitocina
OXT
OXYTOCIN
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
PITOCIN
SID29217903
SID50111741
SYNTOCINON
SYNTOMETRINE
SYT670
TTA-121
|
|
2 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
3 |
|
Ritonavir |
Approved, Investigational |
Phase 4 |
|
155213-67-5 |
392622 |
Synonyms:
538, ABT
A-84538
A-84538|ABBOTT-84538|ABT 538|ABT-538|Norvir®|RTV
Abbott 84538
ABBOTT-84538
ABT 538
ABT-538
|
N-[(1S,3S,4S)-1-BENZYL-3-HYDROXY-5-PHENYL-4-{[(1,3-THIAZOL-5-YLMETHOXY)CARBONYL]AMINO}PENTYL]-N~2~-(METHYL{[2-(1-METHYLETHYL)-1,3-THIAZOL-4-YL]METHYL}CARBAMOYL)-L-VALINAMIDE
Norvir
Norvir Sec
NSC-693184
Ritonavir
RITONAVIR RELATED COMPOUNDS MIXTURE
Ritonavirum
|
|
4 |
|
Zinc sulfate |
Approved, Investigational |
Phase 4 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
5 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
6 |
|
Antibodies |
|
Phase 4 |
|
|
|
7 |
|
Trace Elements |
|
Phase 4 |
|
|
|
8 |
|
Micronutrients |
|
Phase 4 |
|
|
|
9 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
10 |
|
Atazanavir Sulfate |
|
Phase 4 |
|
|
|
11 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
12 |
|
gamma-Globulins |
|
Phase 4 |
|
|
|
13 |
|
Rho(D) Immune Globulin |
|
Phase 4 |
|
|
|
14 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
15 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
1177-87-3 |
3680 |
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
2-{1-fluoro-14,17-dihydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl acetic acid
9alpha-Fluoro-16alpha-methylprednisolone acetate
DECADRON-LA
Dexamethasone 21-acetate
|
DEXAMETHASONE ACETATE
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasone acetic acid
Dexamethasoni acetas
|
|
16 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
50-02-2 |
3003 5743 |
Synonyms:
[<sup>3</sup>H]-dexamethasone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9Α-fluoro-16α-methylprednisolone
Adexone
Aeroseb-D
Aeroseb-dex
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Bisu DS
Calonat
Corson
Corsone
Cortisumman
DALALONE
Decacort
Decacortin
Decaderm
Decadron
Decadron Tablets, Elixir
Decadron®|desametasone|fluormethylprednisolone
DECADRON-75
DECADRON-LA
Decagel
Decaject
Decaject l.a.
Decaject-l.a.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
DEX
DEXA
Dexa mamallet
DEXACEN-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexacortin
Dexa-cortisyl
DEXACORTISYL
Dexadeltone
Dexafarma
DEXAFREE
DEXAIR
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
DEXAMETHASONE
Dexaméthasone
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
DEXAMETHASONE METASULFOBENZOATE SODIUM
DEXAMETHASONE PALMITATE
Dexamethasone sodium phosphate
|
DEXAMETHASONE VALERATE
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dexinolon
Dexinoral
Dexone
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
Dexonium
Dexpak
DEXSOL
Dextelan
DEXTENZA
DEXYCU KIT
Dezone
Dinormon
DROPODEX
DXM
DXM833
DXMS
ECR brand OF dexamethasone
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Gammacorten
GPPE EAR SPY
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Tablets
HL-Dex
ICN brand OF dexamethasone
IontoDex
Isopto-dex
ISV-305
KORTICO INJECTION
Lokalison F
Loverine
Luxazone
MARTAPAN
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merz brand 1 OF dexamethasone
Merz brand 2 OF dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
Mymethasone
Naquasone (veterinary)
NEODECADRON
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC-34521
Ocu-trol
Oradexon
OTO-104
OTOMIZE
OZURDEX
Pet derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
Sandoz dexamethasone
SK-Dexamethasone
SOFRADEX
SPERSADEX COMP
Spoloven
Sunia sol D
Superprednol
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
Visumetazone
|
|
17 |
|
Liver Extracts |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
HIV Protease Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
protease inhibitors |
|
Phase 2, Phase 3 |
|
|
|
Synonyms:
|
20 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Dexamethasone 21-phosphate |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Hormone Antagonists |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Antiemetics |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
glucocorticoids |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
BB 1101 |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Anti-Inflammatory Agents |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Gastrointestinal Agents |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
30 |
|
Inotuzumab ozogamicin |
Approved, Investigational |
Phase 2 |
|
635715-01-4 |
|
Synonyms:
BESPONSA
Besponsa®|CMC-544
CMC-544
INOTUZUMAB OZOGAMICIN
|
PF-05208773
WAY-207294
WAY-207294 CMC-544
|
|
31 |
|
Asparaginase Escherichia coli |
Approved, Investigational |
Phase 2 |
|
9015-68-3 |
|
Synonyms:
ASPARAGINASE
Asparaginase (E. coli)
COLASPASE
CRASNITIN
ELSPAR
|
Escherichia coli L-asparaginase
L-ASPARAGINASE
L-asparagine amidohydrolase
NSC-109229
Putative L-asparaginase precursor
|
|
32 |
|
Pegaspargase |
Approved, Investigational |
Phase 2 |
|
130167-69-0 |
|
Synonyms:
L-ASPARAGINE AMIDOHYDROLASE
ONCASPAR
Peg/L-asparaginase
Peg-asparaginase
|
Pegaspargasa
PEGASPARGASE
PUTATIVE L-ASPARAGINASE PRECURSOR
|
|
33 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
34 |
|
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium |
Experimental |
Phase 2 |
|
461-06-3 |
|
Synonyms:
CARNITINE
CARNITINE CHLORIDE
|
|
|
35 |
|
Folate |
|
Phase 2 |
|
|
|
36 |
|
Vitamins |
|
Phase 2 |
|
|
|
37 |
|
Vitamin B9 |
|
Phase 2 |
|
|
|
38 |
|
Vitamin B Complex |
|
Phase 2 |
|
|
|
39 |
|
Hematinics |
|
Phase 2 |
|
|
|
40 |
|
Tin mesoporphyrin |
|
Phase 2 |
|
|
|
41 |
|
Ethiodized oil |
Approved, Investigational |
Phase 1 |
|
8008-53-5 |
|
Synonyms:
|
42 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 1 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
43 |
|
Gemcitabine |
Approved |
Phase 1 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
44 |
|
Chlorotrianisene |
Investigational, Withdrawn |
Phase 1 |
|
569-57-3 |
11289 |
Synonyms:
Chloortrianisestrol
Chlorestrolo
Chlorotrianisene
Chlorotrianisenum
Chlorotrianisine
Chlorotrianizen
Chlortrianisen
Chlortrianisene
|
Chlortrianisenum
Chlortrianisestrol
Chlortrianisoestrolum
Chlortrianizen
Clorotrianiseno
NSC-10108
TACE
TRIANISESTROL
|
|
45 |
|
Anti-Retroviral Agents |
|
Phase 1 |
|
|
|
46 |
|
Anti-HIV Agents |
|
Phase 1 |
|
|
|
47 |
|
Antimetabolites |
|
Phase 1 |
|
|
|
48 |
|
Antiviral Agents |
|
Phase 1 |
|
|
|
49 |
|
Albumin-Bound Paclitaxel |
|
Phase 1 |
|
|
|
50 |
|
Anti-Infective Agents |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 114)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels .A Prospective Randomized Controlled Trial. |
Unknown status |
NCT02602301 |
Phase 4 |
Oxytocin |
2 |
A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency |
Unknown status |
NCT02594904 |
Phase 4 |
Yinzhihuang Oral Liquid |
3 |
Efficacy of Reverse Phototherapy With Super Light-emitting Diode(Super-led) in Term and Late Preterm Infants:Randomized and Controlled Clinical Trial |
Unknown status |
NCT01340339 |
Phase 4 |
|
4 |
Utilisation du Dispositif BBloo® Pour le Traitement de l'ictère néonatal : Satisfaction Des Parents et Des Personnels Soignants |
Unknown status |
NCT02156050 |
Phase 4 |
|
5 |
Phase 4 Study of Saccharomyces Boulardii on Indirect Hyperbilirubinemia |
Unknown status |
NCT01411761 |
Phase 4 |
|
6 |
Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants |
Completed |
NCT00288600 |
Phase 4 |
Intravenous Immunoglobulin;Normal saline solution |
7 |
A Randomized Crossover Study of the Effects of Zinc Sulphate Supplementation on Atazanavir/Ritonavir-associated Hyperbilirubinemia |
Completed |
NCT01475227 |
Phase 4 |
1 Solvazinc tablet, day 2 to day 15;1 Solvazinc tablet, day 15 to day 28 |
8 |
Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia |
Unknown status |
NCT03266913 |
Phase 3 |
Probiotic |
9 |
A Randomized Trial of Aggressive or Conservative Phototherapy for Extremely Low Birth Weight Infants |
Completed |
NCT00114543 |
Phase 3 |
|
10 |
Effect of Lipid Intake on Direct Hyperbilirubinemia in Late Preterm and Term Infants With Gastrointestinal Surgical Problems. |
Completed |
NCT01555957 |
Phase 3 |
intravenous lipid |
11 |
Routine Use of Transcutaneous Bilirubinometry Reduces the Need for Blood Sampling in Neonates With Jaundice |
Completed |
NCT00653874 |
Phase 3 |
|
12 |
Improving Health Outcomes for New Mothers and Babies |
Completed |
NCT00360204 |
Phase 3 |
|
13 |
The Effects of Dexamethasone Administration on Jaundice Following Liver Resection: a Randomized Controlled Trial |
Completed |
NCT02991339 |
Phase 2, Phase 3 |
Dexamethasone |
14 |
Cycled Phototherapy: A Safer Effective Method to Control the Serum Bilirubin Of Extremely Premature Infants? |
Recruiting |
NCT03927833 |
Phase 3 |
|
15 |
A Phase 2b Multicenter, Single Dose, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates |
Completed |
NCT01887327 |
Phase 2 |
Stannsoporfin;Placebo |
16 |
Effect of Oral Zinc Given Daily Between Days 2 and 7 of Life to Term or Near Term Neonates With Serum Bilirubin Levels of More Than 6 mg/dL at 24 ± 6 Hours of Life on Hyperbilirubinemia and Phototherapy |
Completed |
NCT00692224 |
Phase 1, Phase 2 |
zinc gluconate;placebo |
17 |
Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns |
Completed |
NCT00004382 |
Phase 2 |
tin mesoporphyrin |
18 |
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia |
Completed |
NCT00004381 |
Phase 2 |
tin mesoporphyrin |
19 |
An Open-Label Study of the Safety and Clinical Pharmacology of Stanate® in Infants At-Risk for Exchange Transfusion |
Completed |
NCT00115544 |
Phase 2 |
Stanate |
20 |
Mitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-Asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL) |
Recruiting |
NCT03564678 |
Phase 2 |
Vitamin B Complex |
21 |
A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia |
Terminated |
NCT00850993 |
Phase 2 |
Stannsoporfin |
22 |
A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus |
Completed |
NCT01421355 |
Phase 1 |
Atazanavir |
23 |
Safety of Transarterial Chemoembolization in Patients With Elevated Bilirubin |
Completed |
NCT03259581 |
Phase 1 |
|
24 |
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Investigate the Safety and Pharmacokinetics of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Secondary to Bile Duct Obstruction |
Terminated |
NCT02267707 |
Phase 1 |
nab-paclitaxel;Gemcitabine |
25 |
Safe Threshold to Discontinue Phototherapy in Term and Late Preterm Infant With Hemolytic Disease of Newborn: A Randomized Controlled Trial |
Unknown status |
NCT04218318 |
|
|
26 |
Comparison of Double Pad Fiber Optic Device Versus Conventional Phototherapy for Treatment of Neonatal Hyperbilirubinemia |
Unknown status |
NCT04585828 |
|
|
27 |
Comparison Between Effect of Conventional, Intensive and Light Emitting Diodes (LED) Phototherapy on Oxidative Stress Among Neonates With Unconjugated Hyperbilirubinemia |
Unknown status |
NCT03074292 |
|
|
28 |
Investigation of the Effect of Support Provided for Breastfeeding and the Feeding of Infants' With Breast Milk on Hospitalization Due to Jaundice |
Unknown status |
NCT04445675 |
|
|
29 |
Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform. |
Unknown status |
NCT00154960 |
|
|
30 |
A Prospective Cohort Study on the Etiology of Neonatal Hyperbilirubinemia in a Migrant and Refugee Population on the Thai-Myanmar Border |
Unknown status |
NCT02361788 |
|
|
31 |
The Influence of Phototherapy Lights on the Measurement of Oxygen Saturation With Pulse Oximeter in Newborns. |
Unknown status |
NCT04494217 |
|
|
32 |
Effect of Phototherapy on Serum Level of Calcium in Infants With Hyperbilirubinemia |
Unknown status |
NCT04215601 |
|
|
33 |
Role of Fluid Supplementation in Neonatal Unconjugated Hyperbilirubinemia |
Unknown status |
NCT03684499 |
|
|
34 |
Hyperbilirubinemia After Major Cardiac or Thoracic Aorta Surgery: Predictors and Clinical Significance |
Unknown status |
NCT01617902 |
|
|
35 |
Trial of a New Phototherapy Device for Treating Hyperbilirubinemia in Crigler-Najjar Patients : a New Concept |
Unknown status |
NCT02356978 |
|
|
36 |
Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants? |
Unknown status |
NCT01944696 |
|
|
37 |
Chest Shielding for Prevention of a Patent Ductus Arteriosus in Preterm Infants Receiving Phototherapy Effect of Phototherapy |
Unknown status |
NCT03675425 |
|
|
38 |
The Use of Glycerin Suppositories to Reduce Hyperbilirubinemia in Premature Infants Requiring Phototherapy |
Completed |
NCT01746511 |
|
glycerin suppository |
39 |
Baseline Assessment of Neonatal Hyperbilirubinaemia in a Cohort of New-borns in Kinshasa, Democratic Republic of Congo |
Completed |
NCT03880591 |
|
|
40 |
A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204 |
Completed |
NCT02000830 |
|
Stannsoporfin;Placebo |
41 |
Multi-center Clinical Study on Early Screening and Treatment of Hyperbilirubinemia of Term and Late-preterm Neonates |
Completed |
NCT03824990 |
|
|
42 |
Is Primiparity a Risk Factor for Neonatal Hyperbilirubinemia? |
Completed |
NCT03329040 |
|
|
43 |
A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202 |
Completed |
NCT02033096 |
|
Stannsoporfin;Placebo Control |
44 |
Identification of Jaundice in Newborns Using Smartphones |
Completed |
NCT04182555 |
|
|
45 |
Conventional Versus LED Phototherapy and Their Effect on Lymphocytes Subsets of Full Term Neonates With Hyperbilirubinemia |
Completed |
NCT04373980 |
|
|
46 |
Evaluation of a Smartphone Based Optical Diagnostic Tool for Neonatal Jaundice |
Completed |
NCT03007563 |
|
|
47 |
Bilicurves: Using Information Technology to Integrate Clinical Practice Guidelines Into the Management of Neonatal Hyperbilirubinemia |
Completed |
NCT00801619 |
|
|
48 |
Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns |
Completed |
NCT03599258 |
|
|
49 |
Effects of Probiotics on Neonatal Hyperbilirubinemia |
Completed |
NCT02807246 |
|
|
50 |
Influence of Umbilical Cord Clamping Time in the Newborn, Secondary Neonatal Morbidity and Iron Deposits in the Neonate |
Completed |
NCT03624335 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Phenobarbital
|
Phenobarbital Sodium
|
|